Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA methylation pattern (null)
- Target
- null
- Molecular classification
- Other (specifically, epigenetic modification/state, not a discrete molecule, protein, or receptor)
01
Overview
DNA methylation pattern refers to the distribution and arrangement of methyl groups added to the DNA molecule, primarily at cytosine bases in CpG dinucleotides via the action of DNA methyltransferases (DNMTs). This epigenetic marking influences gene regulation by repressing or permitting transcription, shaping cell-type identity, and controlling key processes such as development, genomic imprinting, X-chromosome inactivation, and suppression of transposable elements. Aberrations in DNA methylation patterns are implicated in cancer, aging, autoimmune diseases, and various neurological disorders. Therapeutic agents targeting DNA methylation primarily act by modulating the activity of enzymes that establish or remove these marks[1][2][3][4][5][6][7].
- Other names
- DNA methylation5-methylcytosine patternDNAme patternepigenetic methylation pattern
02
Mechanism of action
Inhibition or modulation of DNA methyltransferases (e.g., azacitidine acts to inhibit DNMT enzymes, leading to hypomethylation and reactivation of silenced genes)
03
Biological functions
Gene expression regulation (by repressing or activating transcription based on methylation status of gene promoters)Cellular differentiation (establishment of cell-specific methylation landscapes drives lineage specification)Genomic imprinting (parent-of-origin-specific gene expression)X-chromosome inactivationSuppression of transposable elementsControl of cell fateOther (maintenance of genomic stability, epigenetic memory)
04
Disease associations
Cancer (aberrant methylation can silence tumor suppressor genes or activate oncogenes)Aging (age-related changes in global and local DNA methylation patterns)Autoimmune disease (changes in methylation pattern implicated in lupus, SLE, etc.)Neurodevelopmental and neurodegenerative disease (altered methylation pattern in neuronal function, imprinting disorders)Other: imprinting disorders, cardiovascular disease (emerging evidence)
05
Safety considerations
Off-target effects of demethylation (risk of activating oncogenes or silencing critical genes)Epigenetic drift or instability (unintended alteration of cellular identity, increased genome instability)Cytotoxicity, myelosuppression, mutagenicity associated with DNA methylation inhibitors
06
Interacting drugs
DNA methylation inhibitors and modulators such as azacitidine, decitabine (target DNA methyltransferases to modulate methylation patterns indirectly)
07
Biomarkers
Methylation status at specific gene loci (such as MGMT, BRCA1, MLH1 for certain cancers)Global DNA methylation levels (e.g., LINE-1)Methylation of imprinted regions (diagnostic in imprinting disorders)
Beyond the preview
Go deeper on DNA methylation pattern (null).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA methylation pattern (null).